• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4643691)   Today's Articles (485)   Subscriber (50610)
For: Huang Y, Zhang L. Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022. Cancer Innov 2023;2:25-35. [PMID: 38090373 PMCID: PMC10686144 DOI: 10.1002/cai2.56] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/21/2023] [Accepted: 01/31/2023] [Indexed: 10/15/2024]
Number Cited by Other Article(s)
1
Wei M, Shen X, Liu Y, Chen X, Su S, Lv X, Qian X, Yu L, Wang L. The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment. Front Oncol 2024;14:1447828. [PMID: 39267851 PMCID: PMC11390397 DOI: 10.3389/fonc.2024.1447828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Accepted: 08/09/2024] [Indexed: 09/15/2024]  Open
2
Chen J, Yang J, Liu Y, Zhao X, Zhao J, Tang L, Guo M, Zhou Y, Chen C, Li D, Wen Z, Liang G, Xu L. MAPK4 facilitates angiogenesis by inhibiting the ERK pathway in non-small cell lung cancer. CANCER INNOVATION 2024;3:e117. [PMID: 38947754 PMCID: PMC11212285 DOI: 10.1002/cai2.117] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 06/24/2023] [Accepted: 08/24/2023] [Indexed: 07/02/2024]
3
Chen L, Yao N, Yang H, Zhang S, Zhang K. Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach. Cancer Chemother Pharmacol 2024;93:107-119. [PMID: 37838624 DOI: 10.1007/s00280-023-04598-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Accepted: 09/20/2023] [Indexed: 10/16/2023]
4
Xue J, Lyu Q. Challenges and opportunities in rare cancer research in China. SCIENCE CHINA. LIFE SCIENCES 2024;67:274-285. [PMID: 38036799 DOI: 10.1007/s11427-023-2422-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Accepted: 06/15/2023] [Indexed: 12/02/2023]
5
Huang Y, Zhang L. Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022. CANCER INNOVATION 2023;2:25-35. [PMID: 38090373 PMCID: PMC10686144 DOI: 10.1002/cai2.56] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/21/2023] [Accepted: 01/31/2023] [Indexed: 10/15/2024]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA